[Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population]. - Archive ouverte HAL
Article Dans Une Revue Therapies Année : 2023

[Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].

L’aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill ? Étude de simulation sur une population virtuelle réaliste

Résumé

The polypill strategy could become widely accepted in cardiovascular prevention due to reduced costs and its simplicity, which promote compliance. Aspirin is often included as a component of the polypill for primary prevention, but three powerful recent trials failed to show any favorable net benefit even in high-risk subgroups. Our objective is to estimate the net benefit associated with aspirin in primary cardiovascular prevention.
Fichier non déposé

Dates et versions

hal-04726185 , version 1 (08-10-2024)

Identifiants

Citer

Mor Fall, Guillaume Grenet, Hai-Ha Le, Behrouz Kassaï, Jean-Christophe Lega, et al.. [Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].. Therapies, 2023, 78 (6), pp.667-678. ⟨10.1016/j.therap.2023.01.011⟩. ⟨hal-04726185⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More